Giovannoni G, et al. Cladribine tablets in high disease activity (HDA) subgroups from the CLARITY study of patients with relapsing multiple sclerosis (RMS). EP1157. EAN 2017.
Vergoeding selumetinib (Koselugo) voor kinderen met neurofibromatose type 1
mei 2024